Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

Cite this: Speed of Recovery from Acute Exacerbations of Chronic Obstructive Pulmonary Disease after Treatment with Antimicrobials - Medscape - Jul 01, 2003.

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

“Patients with mild-to-moderate COPD who have low exercise tolerance are likely to experience poor respiratory health outcomes,” the investigators concluded. “Exercise tolerance may be considered one ...

Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

Researchers have identified new lung function and blood test cutoffs to improve timely chronic hypercapnia management in ...

Medicare Part D and Medicare Advantage (Part C) plans with drug coverage typically cover inhalers for COPD. But you may still be responsible for a portion of the cost. If you have chronic ...

A 4-month regimen recommended for drug-susceptible TB and 6-month regimen recommended for drug-resistant TB.

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

LOS ANGELES -- For surgeons already split on their preference of inhaled pulmonary vasodilator to prevent postoperative right ...

Inhalers for COPD provide steroids, bronchodilators, or combination drugs. The three types differ in the mechanism by which the medication is inhaled and have different instructions for use.